drugset / Trial / NCT00099060
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to see how well it works in treating patients with recurrent glioblastoma multiforme.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 750 mg | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |